Homocysteine-dependent cardiac remodeling and endothelial-myocyte coupling in a 2 kidney, 1 clip Goldblatt hypertension mouse model

Canadian Journal of Physiology and Pharmacology

Volumn 83, Issue 7, 2005, Pages 583-594

  Tyagi, Neetu ^a   Moshal, Karni S ^a   Lominadze, David ^a   Ovechkin, Alexander V ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Arteriosclerosis; Collagen; Cystathione synthase; ECM; Elastin; Nitric oxide; Renal mechanism

Indexed keywords

3 NITROTYROSINE; ACETYLCHOLINE; BRADYKININ; CIGLITAZONE; COLLAGEN; GELATINASE A; GELATINASE B; HOMOCYSTEINE; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; SILVER; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CLAMP; ARTICLE; BLOOD LEVEL; CELL INTERACTION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROSING ALVEOLITIS; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL ARTERY; RENOVASCULAR HYPERTENSION; TISSUE HOMOGENATE; VASCULAR ENDOTHELIUM;

ACETYLCHOLINE; ANIMALS; BLOTTING, WESTERN; COLLAGEN; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FIBROSIS; HOMOCYSTEINE; HYPERTENSION, RENOVASCULAR; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; NITROPRUSSIDE; PPAR GAMMA; PROTEINURIA; THIAZOLIDINEDIONES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TYROSINE; VASODILATOR AGENTS; VENTRICULAR REMODELING;

EID: 27744470573     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y05-047     Document Type: Article

References (40)

1. Aimes, R,T, and Quigley, J.P. 1995. MMP-2 is an interstitial collagenase. J. Biol. Chem. 270: 5872-5876.
2. Bissonnette R., Treacy, E., Rozen, R., Boucher, B., Cohn, J.S., and Genest, J. 2001. Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis, 155: 455-462.
3. Christen, W.G., Ajani, U.A., Glynn, R.J., and Henneckens, C.H. 2000. Blood levels of Hcy and increased risks of CVD: causal or casual? Arch. Intern. Med.160(4): 422-434.
4. Evans, M., Anderson, R.A., Graham, J., and Ellis, G.R. 2000. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation, 101: 1773-1779.
5. Frantzen, F., Faaren, A.L., Alfheim, I., and Nordhei A.K. 1998. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin. Chem. (Washington, D. C). 44(2): 311-316.
6. Gattuso, A., Mazza, R., Pellegrino, D., and Tota, B. 1999. Endocardial endothelium (EE) mediates luminal acetylcholine-nitric oxide signaling in isolated frog heart. Am. J. Physiol. 276: H633-H641.
7. Huang, G.Y., and Linask, K.K. 1998. Doppler Echo analysis of effects of tribromoethanol anesthesia on cardiac function in mouse embryo: a comparison with pentababital. Lab. Anim. Sci. 48: 206-209.
8. Hunt, M.J., and Tyagi, S.C. 2002. Peroxisome proliferators compete and ameliorate endocardial endothelial cells activation. Am. J. Physiol. 283: C1073-C1079.
9. Inoue, I, Goto, S.S., Matsunaga, T., Nakajima, T., Awara, T., Hokari, S., et al. 2001. The ligands/activators for PPAR alpha and gamma increase Cu-Zn SOD and decrease p22phox message expressions in primary endothelial cells. Metabolism, 50: 3-11.
10. Jones, T.G., and Hancock, J.T. 1994. Assay of plasma membrane NADPH oxidase. Methods. Enzymol. 233: 222-229.
11. Klerk, M., Veroef, P., Clarke, R., Blom, H.J., and Schouten, E.G. 2002. MTHFR study collaboration group. J. Am. Med. Assoc. 288(16): 2023-2031.
12. McCully, K.S. 1969. Vascular pathology of homocysteinemia. Am. J. Pathiol. 56: 111-128.
13. McCully, K.S. 1996. Homocysteine and vascular disease. Nat. Med. 2: 386-389.
14. Mebazaa, A., Wetzel, R., Cherian, M., and Abraham, M. 1995. Comparison between endothelial and great vessel endothelial cells: morphology, growth, and prostaglandin release. Am. J. Physiol. 268: H250-H259.
15. Miller, A., Mujumdar, V., Shek, E., Guillot, J., Angelo, M., Pakmer, L., et al. 2000. Hyperhomocysteinemia induces multiorgan damage. Heart Vessels. 15(3): 135-143.
16. Miller, A., Mujumdar, V., Palmer, L., Bower, J.D., and Tyagi, S.C. 2002. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am. J. Hypertens. 15: 157-163.
17. Mujumdar, V.S., and Tyagi, S.C. 1999. Temporal regulation of ECM components in transition from compensatory hypertrophy to decompensatory heart failure. J. Hypertens. 17: 261-270.
18. Nagase, H., and Woessner, J.F. 1999. Matrix metalloproteinase. J. Biol. Chem. 274: 21491-21494.
19. Nolte, R.T., Wisely, G.B., Westin, S., and Cobb, J.E. 1998. Ligand binding and co-activator assembly of the PPARã. Nature (London), 395: 137-143.
20. Nygard, O., et al. 1997. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Eng. J. Med. 337: 230-236.
21. Pinsky, DJ., Patton, S., Mesaros, S., Brovkovych, V., Kubaszewski, E., Grunfeld, S., et al. 1997. Mechanical transduction of no synthesis in the beating heart. Circ. res. 81: 372-379.
22. Poirier, L.A., Brown, A.T., Fink, L.M., Wise, C.K., Randolph, C.J., Delongchamp, R.R., et al. 2001. Blood SAM concentrations and lymphocyte MTHFR activity in diabetes mellitus and diabetic nephropathy. Metabolism, 50(9): 1014-1018.
23. Qureshi, S.T., Skamene, E., and Malo, D. 1999. Comparative genomics and host resistance against infectious disease. Emerg. Infect. dis. 5: 36-47.
24. Roman, R.J., Ma, Y.H., Frohlich, B., and Markham, B. 1993. Clofibrate prevents the development of hypertrnsion in Dahl salt-senitive rats. Hypertension, 6(2): 985-988.
25. Rucklidge, G.J., Milne, G., McGaw, B.A., Milne, E., and Robins, S.P. 1992. Turnover rates of different collagen types measured by isotope ratio mass spectrometery. Biochim. Biophys. Acta. 11: 1156-1157.
26. Senior, R.M., Griffin, G.L., Eliszar, C.J., Shapiro, S.D., Goldberg, G.I., and Welgus, H.G. 1991. Human 92- and 72- kilodalton type IV collagenases are elastases. J. Biol. Chem. 266: 7870-7875.
27. Simone, G.D., Devereux, R.B., and Camergo, M.J.F. 1992. In vivo LV anatomy in rats with two kidney, one clip and one-kidney, one clip renovascular hypertension. J. Hypertens. 10: 725-732.
28. Smiley, L.M., Camp, T.M., Lucchesi, P.A., and Tyagi, S.C. 2004. Peroxisome proliferator ameliorates endocardial endothelial and muscarinic dysfunction in spontaneously hypertensive rats. Antioxid. Redox Signaling. 6(2): 367-374.
29. Sutton-Tyrrell, K., Bostom, A., Selhub, J., and Ziegler-Johson, C. 1997. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation, 96: 1745-1749.
30. Tarone, R.E. 1990. A modified Bonferroni method for discrete data. Biometrics, 46: 515.
31. Tyagi, S.C. 1997. Proteinases and myocardial extracellular matrix turnover. Mol. Cell. Biochem. 168: 1-12.
32. Tyagi, S.C. 1998. Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. Am. J. Physiol. 274: C396-C405.
33. Tyagi, S.C. 1999. Homocysteine and heart disease: pathophysiology of extracellular matrix. Clin. Exper. Hypertens. 21: 181-198.
34. Tyagi, S.C. 2000. Physiology and homeostasis of extracellular matrix: cardiovascular adaptation and remodeling. Pathophysiology, 7: 177-182.
35. Tyagi, S.C., Smiley, L.M., Mujumdar, V.S., Clonts, B., and Parker, J.L. 1998. Reduction-oxidation (redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in vascular extracellular matrix remodeling and vascular tone. Mol. Cell. Biochem. 181: 107-116.
36. Tyagi, S.C., Smiley, L.M., and Mujumdar, V.S. 1999. Homocysteine impairs endocardial endothelial function. Canad. J. Physiol. Pharmacol. 77: 950-957.
37. Wollesen, E, Brattstrom, L., and Refsum, H. 1999. Plasma total Hcy and cysteine in relation to glomerular filteration rate in diabetes. Kidney Int. 55: 1028-1035.
38. Yamamoto, K., Ohki, R., Lee, R.T., Ikeda, U., and Shimada, K. 2001. PPARã activators inhibit cardiac hypertrophy in cardiomyocytes. Circulation, 104: 1670-1675.
39. Yi, P., Melnyk, S., Pogribna, M., Pogribny, I.P., Hine, R.J., and James, S.J. 2000. Increase in plasma homocysteine associated with parallel increase in plasma s-adenosylhomocysteine and lymphocyte DNA hypomethylation.macology J. Biol. Chem. 275: 29318-29323.
40. Zhang, X., Li, H., Jin, H., Ebin, Z., Brodsky, S., and Goligorsky, M.S. 2000. Effects of homocysteine on endothelial nitric oxide production. Am. J. Physiol. 279: F671-F678.